Want to see PTN full AI Analyst Report?
Top Page
Palatin Technologies
(NASDAQ:PTN)
Select Model
Select Model
Rating:41Neutral
Price Target:
$5.50
▼(-46.96% Downside)
Action:Reiterated
Date:10/19/26
PTN scores low primarily due to weak financial durability—persistent losses, ongoing cash burn, and reliance on additional financing—reinforced by the earnings call’s going-concern and funding-risk disclosures. Technicals further pressure the score with a clear downtrend and negative momentum. Valuation provides limited offset given a non-meaningful negative P/E and no dividend support.
Positive Factors
MC4R Pipeline
A diversified MC4R pipeline gives Palatin several potential paths into rare obesity indications, reducing dependence on one asset. The programs are designed around efficacy, selectivity, tolerability and convenient dosing, which could support differentiated products if clinical development confirms the preclinical promise.
Negative Factors
Going-Concern Funding Risk
Insufficient cash runway is a durable constraint on Palatin’s ability to execute its development plan. Required financing could delay clinical milestones, force reliance on equity or partnership capital, and reduce strategic flexibility if funding is unavailable or obtained on unfavorable terms.
Read all positive and negative factors
Positive Factors
Negative Factors
MC4R Pipeline
A diversified MC4R pipeline gives Palatin several potential paths into rare obesity indications, reducing dependence on one asset. The programs are designed around efficacy, selectivity, tolerability and convenient dosing, which could support differentiated products if clinical development confirms the preclinical promise.
Read all positive factors
Palatin Technologies (PTN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.83M
Dividend YieldN/A
Average Volume (3M)62.16K
Price to Earnings (P/E)―
Beta (1Y)-0.20
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.25
Shares Outstanding1,780,939
10 Day Avg. Volume35,702
30 Day Avg. Volume62,157
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.56
Price to Sales (P/S)2.31
P/FCF Ratio-2.25
Enterprise Value/Market Cap3.56
Enterprise Value/Revenue2.66
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-4.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$11.67M
Palatin Technologies Business Overview & Revenue Model
Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R ago...
Palatin Technologies Earnings Call Summary
Earnings Call Date:Sep 28, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The call conveyed strong optimism about Palatin's technical progress, preclinical MC4R data, collaboration activity and planned clinical development. However, the positive outlook is materially offset by the explicit going-concern warning, the need for additional financing before development milestones can proceed, higher expected operating expenses and the prior toxicity issue in the oral program. Overall, the tone was cautiously optimistic but financially constrained.Positive Updates
Strategic Focus on Rare Obesity Disorders
Palatin is prioritizing next-generation, best-in-class melanocortin-4 receptor (MC4R) agonists for hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome, with potential applicability to other MC4R-pathway disorders.
Negative Updates
Going-Concern Warning and Funding Requirement
Palatin stated that its $7.5 million cash balance at June 30, 2026, together with current operating and development plans, is not expected to be sufficient to fund operations for at least 12 months following issuance of the financial statements. Substantial doubt exists about the company's ability to continue as a going concern, and additional financing is required to advance development programs and fund operations.
Read all updates
Q4-2026 Updates
Positive
Negative
Strategic Focus on Rare Obesity Disorders
Palatin is prioritizing next-generation, best-in-class melanocortin-4 receptor (MC4R) agonists for hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome, with potential applicability to other MC4R-pathway disorders.
Read all positive updates
Company Guidance
Subject to appropriate funding, Palatin is targeting initiation of a Phase I single ascending dose and multiple ascending dose studies for its lipidated peptide candidate in the first half of calendar 2027, with data targeted for the second half of 2027, and initiation of oral Phase I single ascending dose and multiple ascending dose studies in the second half of calendar '27, with initial data expected in the first half of 2028; the multiple ascending dose studies will treat healthy obese patients for 28 days. Palatin anticipates and expects to receive a milestone from Boehringer Ingelheim sometime within the next 2 to 3 quarters, while Altanispac is a little further out, and said it would not be surprised if someone does pull the trigger on a research or an early-stage collaboration within the next several quarters. Operating expenses are expected to increase over the next several quarters, including the quarter ended 12/31, the first quarter or even the first half of '27, to around what we've done in the first few quarters of calendar '26, but “it's not going to double.” The Series J warrant could yield approximately $18.5 million if exercised at 100%, triggered by the lesser of 18 months or the IND filing of 1 of Palatin's internal obesity MC4R compounds, and additional financing will be required because existing cash is not expected to be sufficient to fund operations for at least 12 months following issuance of the financial statements.Palatin Technologies Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.19M | 0.00 | 4.49M | 4.85M | 1.47M |
| Gross Profit | 13.12M | 0.00 | 4.39M | 4.44M | 1.25M |
| EBITDA | -8.61M | -17.03M | -29.38M | -28.40M | -36.04M |
| Net Income | -8.38M | -17.31M | -29.74M | -24.04M | -36.20M |
Balance Sheet | |||||
| Total Assets | 8.52M | 3.27M | 10.74M | 17.94M | 36.07M |
| Cash, Cash Equivalents and Short-Term Investments | 7.49M | 2.56M | 9.53M | 10.98M | 29.94M |
| Total Debt | 223.68K | 163.78K | 590.34K | 1.05M | 1.15M |
| Total Liabilities | 1.84M | 8.04M | 10.85M | 19.92M | 19.80M |
| Stockholders Equity | 6.69M | -4.78M | -111.50K | -1.98M | 16.27M |
Cash Flow | |||||
| Free Cash Flow | -13.58M | -21.31M | -31.50M | -28.85M | -30.18M |
| Operating Cash Flow | -13.53M | -21.31M | -31.46M | -28.42M | -29.92M |
| Investing Cash Flow | -51.30K | 3.13M | 12.45M | -3.43M | -261.37K |
| Financing Cash Flow | 18.51M | 11.21M | 20.55M | 9.90M | 18.36K |
Palatin Technologies Technical Analysis
Negative
10.37
Price Trends
9.76
Negative
10.01
Negative
14.39
Negative
Market Momentum
-1.23
Positive
22.58
Positive
3.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTN, the sentiment is Negative. The current price of 10.37 is above the 20-day moving average (MA) of 8.07, above the 50-day MA of 9.76, and below the 200-day MA of 14.39, indicating a bearish trend. The MACD of -1.23 indicates Positive momentum. The RSI at 22.58 is Positive, neither overbought nor oversold. The STOCH value of 3.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTN.
Palatin Technologies Risk Analysis
Palatin Technologies disclosed 48 risk factors in its most recent earnings report. Palatin Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palatin Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $13.36M | -0.86 | -64.75% | ― | -62.70% | -121.27% | |
46 Neutral | $15.74M | -1.29 | -569.36% | ― | ― | 63.72% | |
44 Neutral | $13.53M | -0.87 | -748.08% | ― | ― | ― | |
41 Neutral | $9.83M | -1.06 | -115.00% | ― | ― | ― | |
41 Neutral | $4.78M | -0.14 | -223.19% | ― | -42.74% | 20.66% |
* Healthcare Sector Average
PTN
Palatin Technologies
5.51
-0.39
-6.61%
DARE
Daré Bioscience
0.65
-1.44
-68.85%
LPCN
Lipocine
1.46
-1.33
-47.67%
BCDA
BioCardia
0.93
-0.47
-33.71%
LGVN
Longeveron
1.59
-6.91
-81.29%
Palatin Technologies Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Palatin Technologies Shareholders Back Governance and Incentive Plan
Positive
Aug 3, 2026
On July 28, 2026, Palatin Technologies held its annual meeting of stockholders, with 54.3% of eligible votes represented in person or by proxy. Shareholders elected four directors to serve until the next annual meeting and ratified the appointment...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.